Status:
TERMINATED
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Conditions:
Astrocytoma
Oligodendroglioma
Eligibility:
All Genders
18+ years
Brief Summary
MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblas...
Eligibility Criteria
Inclusion
- Inclusion/Exclusion Criteria:
- 18 years of age
- Brain tumor(s) to be resected for clinical reasons.
- Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV.
- Adequate tissue available for processing as determined by Pathology.
- Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment.
- Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy.
Exclusion
Key Trial Info
Start Date :
October 9 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 25 2025
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT01849952
Start Date
October 9 2013
End Date
August 25 2025
Last Update
September 15 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Tufts Medical Center
Boston, Massachusetts, United States, 02111
2
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
3
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
4
University of Vermont
Burlington, Vermont, United States, 05405